Q3 is behind us and 2023 is approaching, both with uncertainties and opportunities. While a pretty brutal market correction has made for a rough ride in biotech, the fundamentals of the industry remain strong. However, this doesn't mean that dealmaking is straightforward (was it ever?). Big pharma and biotech alike need to look at ways to get creative in a fundamentally strong but technically very volatile market.